Abstract P2-05-20: Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotypeMV Dieci, Valeria Guarneri, Cristina Ghiotto et al.|Cancer Research|2017Cited by 3
Abstract P4-08-04: PD-L1 expression and prognosis in triple negative breast cancer (TNBC): An analysis of 265 patients (pts) treated with standard therapy for stage I-III diseaseMV Dieci, PierFranco Conte, Enrico Orvieto et al.|Cancer Research|2019Cited by 2
Abstract P1-12-06: Factors related to the prognosis of breast cancer patients after the development of brain metastasesGaia Griguolo, Valentina Guarneri, MV Dieci et al.|Cancer Research|2017Cited by 0
Abstract P6-18-24: Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patientsSimona Frezzini, Valentina Guarneri, Tommaso Giarratano et al.|Cancer Research|2019Cited by 0
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialCharles M. Perou, Ana Vivancos, PierFranco Conte et al.|UNC Libraries|2024Cited by 0